Skip to content
Screener

Pre-Tax Income at other companies

Schrodinger logo
SchrodingerSDGR
$7.35M+117%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
-$43.98M-12.3%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
-$131.01M+23.8%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$57.19M-6.9%
Absci Corporation logo
Absci CorporationABSI
-$29.58M-12.3%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$36.34M-75.1%

Other financials

Income statement

See full
Revenue$4.1M-76.3%
Operating income-$62.8M-26.6%
Net income-$55.4M-59.6%
EPS (diluted)-$0.18-50.0%

Balance sheet

See full
Cash & equivalents$145.1M+23.5%
Total debt$135.6M-4.5%
Total equity$896.0M-11.0%
Total assets$1.3B-6.7%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$2.1M-84.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.99B+62.2%
Enterprise value$1.98B+58.2%
P/S30.1×-7.3×

Profitability

See full
Operating margin-340.3%-127pp
Net margin-248.8%-83.6pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-17.3%+2.1pp
Debt / equity0.2×0.0×
Current ratio12.8×+1.7×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001703057-26-000046
Line itemThree months ended June 30, 2025Three months ended June 30, 2026Six months ended June 30, 2025Six months ended June 30, 2026
Interest and other(9,549)42(15,073)(3,606)
Grants and incentives(3,692)(3,854)(7,845)(8,193)
Total other income(13,241)(3,812)(22,918)(11,799)
Loss before income tax(36,344)(58,965)(89,328)(108,501)
Income tax recovery(1,617)(3,538)(8,980)(9,909)
Net loss$(34,727)$(55,427)$(80,348)$(98,592)
Foreign currency translation adjustment4,341(733)1,7211,082
Comprehensive loss$(30,386)$(56,160)$(78,627)$(97,510)

Item 1. Financial Statements (Unaudited)

FAQ

What is AbCellera Biologics Inc.'s pre-tax income?
AbCellera Biologics Inc. (ABCL) reported pre-tax income of -$58.97M in Q2 2026.
How has AbCellera Biologics Inc.'s pre-tax income changed year-over-year?
AbCellera Biologics Inc.'s pre-tax income decreased by 62.2% year-over-year, from -$36.34M to -$58.97M.
What is the long-term trend for AbCellera Biologics Inc.'s pre-tax income?
Over 3 years (2021 to 2025), AbCellera Biologics Inc.'s pre-tax income has grown at a -6.8% compound annual growth rate (CAGR), from $219.15M to -$177.6M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about AbCellera Biologics Inc.'s pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude